Triptorelin to protect ovaries in young women with cancer
Part of Blood & lymphatic, Cancer, Women’s health & pregnancy clinical trials.
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 40 years old and have started your period (more than 6 months ago).
- You have been diagnosed with your first cancer (not breast cancer).
- Your planned chemotherapy includes a strong drug called an alkylating agent (like cyclophosphamide, ifosfamide, or others).
- You have not had radiation to your pelvis or high-dose radiation to your brain.
- You are not pregnant, not breastfeeding, and agree to use birth control during the study.
- You do not have a condition like Turner syndrome, Fragile X, or Down syndrome that affects fertility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.
This trial studies freezing (cryopreserving) ovarian tissue before treatment that may permanently affect fertility and hormone production. You might consider it if you are planning surgery, chemotherapy, or radiation soon and want to preserve future options.
This study looks at how immunotherapy combined with chemotherapy affects ovary function in younger women with early-stage triple-negative breast cancer. It aims to understand if this treatment impacts fertility, which can help patients make informed decisions.
This trial tests a drug called GnRH agonist to see if it helps people with endometriosis cysts. It might offer a new treatment option for those with this condition.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.